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Summary
Background Fumaric acid esters (FAEs) are recommended in international guideli-
nes for induction and long-term treatment of adults with moderate-to-severe
chronic plaque psoriasis. The fixed combination Fumaderm is approved in Ger-
many, with dimethyl fumarate (DMF) being the main active ingredient.
Objectives To assess the efficacy and safety of a new formulation of DMF
(LAS41008), compared with placebo and Fumaderm®, in adults with moderate-
to-severe chronic plaque psoriasis.
Methods In this phase III, double-blind, placebo-controlled, noninferiority trial
(BRIDGE, NCT01726933, EudraCT 2012-000055-13), patients were randomized
to receive LAS41008, Fumaderm® or placebo (2 : 2 : 1) for 16 weeks, uptitrat-
ing to a maximum daily DMF dose of 720 mg, depending upon individual
response. The coprimary end points were the percentage of patients achieving
≥ 75% improvement in Psoriasis Area and Severity Index (PASI 75) and the per-
centage achieving a score of ‘clear’ or ‘almost clear’ in the Physician’s Global
Assessment (PGA) at week 16.
Results In total, 671 patients were randomized and included in the full analysis set
(n = 267, LAS41008; n = 273, Fumaderm®; n = 131, placebo). At week 16,
375% of patients treated with LAS41008 achieved PASI 75, compared with
153% receiving placebo (superiority for LAS41008 vs. placebo: P < 0001) and
403% receiving Fumaderm® (noninferiority for LAS41008 vs. Fumaderm®:
P < 0001). Overall, 33% of patients treated with LAS41008 were ‘clear’ or ‘al-
most clear’ in the PGA at week 16, compared with 130% receiving placebo
(P < 00001; LAS41008 superiority vs. placebo) and 374% receiving Fuma-
derm®. Most treatment-related adverse events were classed as ‘mild’ in severity.
Conclusions LAS41008 (DMF) is effective in the treatment of adults with moderate-
to-severe chronic plaque psoriasis.
What’s already known about this topic?
• A combination of fumaric acid esters (FAEs), including dimethyl fumarate (DMF),
is approved for the treatment of moderate-to-severe psoriasis in Germany, with a
positive risk–benefit profile for long-term use.
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• Despite being recommended in international treatment guidelines, FAEs are not
available in most European countries.
What does this study add?
• This international, randomized, double-blind trial demonstrates the efficacy and
safety of LAS41008 (DMF) for the treatment of adults with moderate-to-severe
chronic plaque psoriasis.
Psoriasis is a chronic, inflammatory, immune-mediated skin
condition, with its prevalence varying according to geo-
graphical location. It affects approximately 2–4% of adults
in Europe,1 can be associated with important comorbidity,
including cardiovascular and metabolic diseases,2 and has a
significant negative physical and psychosocial impact on
quality of life.3
Up to one-third of patients with psoriasis have a moderate-
to-severe form of the disease,4,5 defined by a European
consensus as body surface area (BSA) involvement > 10% or
Psoriasis Area and Severity Index (PASI) > 10 and Dermatol-
ogy Life Quality Index (DLQI) > 10.6 Currently available sys-
temic treatments for moderate-to-severe psoriasis include both
small molecules and biologics. Responses to systemic therapies
vary according to the individual patient and are associated
with drug-specific side-effects. Therefore, there is a need for
new systemic treatment options that provide a good balance
of efficacy and safety, especially in the long term.7
Fumaric acid esters (FAEs) were first investigated for the
treatment of psoriasis in 1959. Since 1994, a combination of
FAEs, including dimethyl fumarate (DMF) together with cal-
cium, magnesium and zinc salts of monoethyl fumarate (MEF)
in two different strengths (Fumaderm Initial, Fumaderm,
Biogen Idec GmbH, Germany), has been approved in Ger-
many, where it has demonstrated a favourable efficacy and
safety profile.8,9
Dimethyl fumarate is considered the main active compo-
nent in the combination,10 as the MEF salts alone have not
been shown to have significant clinical efficacy.11 The precise
mode of action of DMF in psoriasis is not fully understood.
DMF is a prodrug that is rapidly converted after oral intake
to monomethyl fumarate, which, together with a DMF–glu-
tathione adduct, is the most prominent metabolite.12 FAEs
are known to affect several intracellular pathways with
antioxidant, anti-inflammatory and immunomodulating
effects.13 DMF treatment promotes the generation of inter-
leukin-10-producing type II dendritic cells, polarizing the
immune response towards a T helper cell 2 phenotype.14
FAEs also modulate the nuclear factor (erythroid-derived 2)-
like 2 transcriptional pathway, which is required for antioxi-
dant activity.15
Treatment of moderate-to-severe psoriasis with FAEs has
been shown to be efficacious and safe in the long term.9 Euro-
pean guidelines for the treatment of psoriasis recommend
FAEs for both induction and long-term treatment.16 Although
this treatment remains unlicensed in many countries, there is
known use of FAEs in several parts of Europe, especially in
patients who fail, or are intolerant to, classic systemic
therapies.16
The BRIDGE trial was designed to investigate the efficacy
and safety of LAS41008 (DMF) for the treatment of adults
with moderate-to-severe chronic plaque psoriasis.
Patients and methods
Trial design
This was a multicentre, randomized, double-blind, three-arm,
phase III trial (clinicaltrials.gov NCT01726933; EudraCT 2012-
000055-13) conducted in Austria, Germany, the Netherlands
and Poland in adults with moderate-to-severe chronic plaque
psoriasis. Patients were recruited from January 2013 and
randomized to receive either LAS41008 (DMF), Fumaderm®
(active comparator) or placebo in a randomization schedule of
2 : 2 : 1 for a 16-week treatment phase, with a subsequent off-
treatment follow-up of up to 12 months.
Randomization was performed by the investigators using an
interactive web-based response system. The randomization
sequence was kept concealed from the investigators during the
trial. Treatment was uptitrated over the first 9 weeks, with
placebo or up to a maximum daily dose of 720 mg DMF in
the LAS41008 or Fumaderm® groups (Fig. 1, Table 1), as per
clinical practice. After week 4, a reduction to the last tolerated
dose was permitted in case of intolerability.
Following completion of an initial 16-week treatment per-
iod, patients entered a 12-month treatment-free follow-up
period to assess safety, rebound and persistence of effect.
Patients
Patients were randomized if they were aged 18 years or older
and had a diagnosis of moderate-to-severe, chronic (for
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≥ 12 months) plaque psoriasis. Moderate to severe was
defined as PASI > 10, BSA > 10% and PGA ≥ 3 (i.e. moderate
or greater on a scale of 0–5). All previously treated patients
underwent a washout period (2 weeks for topical treatments,
1 month for conventional systemic drugs and phototherapy,
3 months for biologics). The use of topical and/or additional
systemic treatments was not allowed during the trial. Patients
who had previously failed therapy on FAEs due to lack of effi-
cacy or tolerability were excluded, as were patients with base-
line leucocyte counts < 3 9 109 cells L1 and/or lymphocyte
counts < 1 9 109 cells L1, and pregnant or breastfeeding
women.
Assessments
Efficacy was assessed considering the European Medicines
Agency’s clinical investigation guidance17 using the PASI, PGA
(six-point scale) and BSA scores, which were measured at
screening, baseline, weeks 3, 8 and 16 and each follow-up
visit (Fig. 1).
Fig 1. Trial design. BID, twice daily; QD, once daily; R, randomization; TID, three times daily. In the first 3 weeks, 30-mg dimethylfumarate
tablets were used, and as the LAS41008 30-mg and Fumaderm® Initial tablets differed in colour and size, a double-dummy technique was used,
with each patient also receiving one placebo tablet per tablet of LAS41008 or Fumaderm®. Subsequent uptitration was achieved using
indistinguishable 120-mg tablets. aTrial-centre visits at weeks 12 and 16; Psoriasis Area and Severity Index (PASI), Physician’s Global Assessment
(PGA) and body surface area (BSA) at week 16 only.
Table 1 Dosing schedule of dimethyl fumarate (DMF)
Week
Number of tablets
Daily dose of
DMF (mg)Morning Midday Evening
30 mg DMF per tablet, double dummy
1 – – 1 (+ 1 dummy) 30
2 1 (+ 1 dummy) – 1 (+ 1 dummy) 60
3 1 (+ 1 dummy) 1 (+ 1 dummy) 1 (+ 1 dummy) 90
120 mg DMF per tablet
4 – – 1 120
5 1 – 1 240
6 1 1 1 360
7 1 1 2 480
8 2 1 2 600
9–16 2 2 2 720
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End points
The two coprimary efficacy end points were the percentage of
patients achieving PASI 75 (≥ 75% improvement of PASI vs.
baseline, considered clinically meaningful)6 and the percent-
age of patients achieving a score of 0 or 1 (‘clear’ or ‘almost
clear’) in the PGA, both evaluated at week 16 (end of treat-
ment) (Fig. 1).
Secondary end points included PASI 75 at weeks 3 and 8, PASI
50 and PASI 90 at week 16, and scores of 0–1 in the PGA at
weeks 3 and 8 and BSA at weeks 3, 8 and 16. Health-related
quality of life was measured using the DLQI score, assessed at
baseline, week 16 and the 2-month follow-up. Rebound, defined
as a worsening of psoriasis over baseline values (PASI ≥ 125%),
was assessed 2 months after the end of treatment.
Adverse events (AEs), haematology and chemistry laboratory
tests, and urinalysis data were collected throughout the treat-
ment period and, if indicated by previous results, potentially
up to 12 months in the off-treatment follow-up period.
Statistical analysis
The sample-size calculations were based on PASI 75 response
rates of 50% and 10% for LAS41008 and placebo, respec-
tively, and ‘clear’/’almost clear’ PGA response rates of 40%
for LAS41008 and 10% for placebo. For the noninferiority test
of LAS41008 vs. Fumaderm® regarding PASI 75 at week 16, a
zero difference was assumed and a noninferiority margin of
15% was set. An alpha level of 005 was defined and a drop-
out rate of 15% was factored into the calculations. A total of
690 patients (276 per active group and 138 in the placebo
group) provided a power of > 99% for the two superiority
tests of LAS41008 vs. placebo, and 90% for the noninferiority
test of LAS41008 vs. Fumaderm®.
An interim analysis was planned once data for the two pri-
mary efficacy variables were available for 230 patients, to
allow sample-size reassessment because of uncertainty in the
response-rate assumptions, stopping for futility and identifica-
tion of safety signals.
All statistical analyses were based on the full analysis set
(FAS) and the per protocol set (PPS). As the results of both
were consistent, data are presented here only for the FAS. A
last-observation-carried-forward approach was used to handle
missing data for the PASI- and PGA-derived end points. A sensi-
tivity analysis was conducted for the coprimary efficacy end
point, treating missing data as ‘nonresponders’. Further details
are included in Appendix S1 (see Supporting Information).
The coprimary efficacy end points, PASI 75 and PGA 0–1 at
week 16, were analysed using the Wald test for risk differ-
ences (differences in responder rates between treatment
groups). A hierarchical approach was used to deal with multi-
ple comparisons – first the superiority tests in PASI 75 and
Table 2 Demographic and baseline patient characteristics (treated population)
LAS41008 (n = 279) Fumaderm® (n = 283) Placebo (n = 137)
Male, n (%) 174 (624) 185 (654) 93 (679)
Age (years)
Mean  SD 440  152 450  138 440  143
Range 18–80 18–87 18–78
Race, n (%)
White 275 (986) 280 (989) 137 (1000)
Black/African American 1 (04) 0 0
Asian 1 (04) 3 (11) 0
Other 2 (07) 0 0
PASI total score, mean  SD 163  57 164  6.79 162  49
PGA group, n (%)a
Moderate 162 (607) 164 (601) 79 (603)
Moderate to severe 93 (348) 94 (344) 49 (374)
Severe 12 (45) 15 (55) 3 (23)
Body surface area (%), mean  SD 219  116 213  125 219  123
Prior conventional systemic therapy, n (%)
Methotrexate 20 (72) 39 (138) 14 (102)
Ciclosporin 12 (43) 8 (28) 8 (58)
Fumaderm® 9 (32) 11 (39) 4 (29)
Acitretin 8 (29) 15 (53) 9 (66)
Apremilast 1 (04) 1 (04) 0
Prior biological therapy, n (%)
Interleukin inhibitorsb 7 (25) 4 (14) 3 (22)
TNF-a inhibitorsc 1 (04) 6 (21) 0
Prior nondrug therapy including phototherapy, n % 75 (269) 86 (304) 43 (314)
PASI, Psoriasis Area and Severity Index; PGA, Physician’s Global Assessment; TNF, tumour necrosis factor. aThe PGA scale was defined as
follows: 0, clear; 1, almost clear; 2, mild; 3, moderate; 4, moderate to severe; 5, severe. bIncluding secukinumab, ustekinumab and
brodalumab. cIncluding adalimumab and etanercept.
© 2016 The Authors. British Journal of Dermatology
published by John Wiley & Sons Ltd on behalf of British Association of Dermatologists.
British Journal of Dermatology (2017) 176, pp615–623
618 Dimethyl fumarate in moderate-to-severe chronic plaque psoriasis, U. Mrowietz et al.
PGA for both the FAS and PPS, and then the noninferiority test
for PASI 75 if superiority vs. placebo was demonstrated.
Safety outcomes were summarized descriptively using the
safety analysis set.
Results
Overall, 839 patients were screened and 704 were random-
ized, with 699 receiving at least one dose of trial medication
and included in the safety analysis set (Appendix S1; see Sup-
porting Information) and 671 in the FAS (267, 273 and 131
patients in the LAS41008, Fumaderm® and placebo groups,
respectively). Patients were recruited from 57 sites throughout
Austria, Germany, the Netherlands and Poland. The baseline
patient characteristics were well balanced across treatment
groups (Table 2). Rates of discontinuations were similar
between the LAS41008 and Fumaderm® arms (371% and
385%, respectively), with the most common reasons for
Fig 2. Participant flow. AE, adverse event; FAS, full analysis set; PPS, per protocol set; SAS, safety analysis set.
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treatment discontinuation being occurrence of an AE in the
LAS41008 (23%) and Fumaderm® arms (24%), and lack of
efficacy in the placebo arm (15%) (Fig. 2).
Efficacy
Coprimary end points
Significantly more patients achieved PASI 75 at week 16 fol-
lowing treatment with LAS41008 than with placebo [375%
vs. 153%, P < 0001; 9924% confidence interval (CI) 107–
337%]. Furthermore, LAS41008 was noninferior to Fuma-
derm® at week 16 (375% vs. 403%, P < 0001; 9924%
CI 140 to 84%) (Fig. 3). At week 16, 330%, 374% and
130% of patients had achieved a score of ‘clear’ or ‘almost
clear’ in the PGA in the LAS41008, Fumaderm® and placebo
groups, respectively, and LAS41008 was significantly superior
to placebo (P < 0001; 9924% CI 90–310%) (Fig. 4).
Concomitant intake of potentially nephrotoxic drugs
(n = 108), such as angiotensin-converting enzyme inhibitors,
angiotensin II inhibitors and/or statins, did not have a signifi-
cant impact on the primary outcome measures or on the
safety profile of LAS41008.
Secondary end points
No statistically significant differences between LAS41008 or
Fumaderm® and placebo were found in the percentage of
patients achieving PASI 75 or PGA 0–1 at weeks 3 or 8 (data
not shown).
The percentage of involved BSA decreased from week 3
onwards in the LAS41008 group, with a significant reduction
at week 8 compared with placebo (P = 0032; 95% CI 293
Fig 3. Percentage of patients achieving ≥ 75% improvement in Psoriasis
Area and Severity Index (PASI 75) at week 16 (full analysis set).
*P < 0001 vs. placebo; †P < 0001 noninferiority vs. Fumaderm®.
Fig 4. Percentage of patients achieving a score of ‘clear’ or ‘almost
clear’ in the Physician’s Global Assessment (PGA) at week 16 (full
analysis set). *P < 0001 vs. placebo.
Fig 5. Mean change from baseline in body surface area (BSA) score at
week 16 (full analysis set). *P < 0001 vs. placebo.
Fig 6. Percentage of patients achieving ≥ 50% improvement in
Psoriasis Area and Severity Index (PASI 50) and PASI 90 at week 16
(full analysis set). *P < 0001 vs. placebo; **P < 00001 vs. placebo.
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to 013). By week 16, continuing improvements in BSA
were reported, which were statistically significant vs. placebo
for both LAS41008 (P < 0001; 95% CI 896 to 482) and
Fumaderm® (P < 0001; 95% CI 810 to 401) (Fig. 5).
Results for the PASI, PGA and BSA assessments were consistent
between the FAS and PPS (data not shown).
Compared with placebo, significantly more patients receiv-
ing LAS41008 achieved PASI 50 at week 16 (536% vs.
290%, P < 0001; 95% CI 147–344%). Similarly, LAS41008
was statistically superior to placebo for the percentage of
patients achieving PASI 90 at week 16 (184% vs. 46%,
P < 0001; 95% CI 79–196%) (Fig. 6).
The mean number of tablets taken during the trial did not
differ significantly among the active treatment arms (Fig. S1;
see Supporting Information).
Rebound at 2 months off treatment
Rebound at 2 months after the end of treatment was recorded
in very few patients in the LAS41008 or Fumaderm® treat-
ment arms (11% and 22%, respectively, vs. 93% of patients
receiving placebo).
Safety
Treatment-emergent AEs (TEAEs) were reported in 839% and
841% of patients in the LAS41008 and Fumaderm® groups,
respectively, and in 599% of patients in the placebo group.
The majority were considered ‘mild’ in intensity (667%,
671% and 526% in the LAS41008, Fumaderm® and placebo
groups, respectively). The most frequently reported TEAEs in
both the LAS41008 and Fumaderm® groups were gastroin-
testinal disorders (627% and 633%, respectively), including
diarrhoea, abdominal pain, nausea and flatulence. Flushing
was also commonly reported (183% and 163%, respectively)
(Table 3).
Lymphopenia was reported in 28 patients (100%) in the
LAS41008 group, with three patients (11%) considered sev-
ere (< 05 9 109 cells L1), and in 30 (106%) patients in
the Fumaderm® group, with two patients (007%) consid-
ered severe. Proteinuria was reported in four patients
(14%) in the LAS41008 group and in six patients (21%)
in the Fumaderm® group. Overall, the frequency and type
of the reported TEAEs were very similar and did not differ
significantly between the LAS41008 and Fumaderm® groups
(Table 3).
Twenty-three serious TEAEs were reported in 22 patients
(32%, 28% and 36% of patients in the LAS41008, Fuma-
derm® and placebo groups, respectively). Only four of these
serious TEAEs, occurring in three patients randomized to
Fumaderm®, were assessed by the investigator as related to
treatment (erosive gastritis, gastritis, gastric ulcer and gastro-
duodenitis). One death considered unrelated to the medication
was reported in a patient receiving Fumaderm® (subendocar-
dial ischaemia). No relationship between blood abnormalities
and the onset of infections was detected.
Laboratory investigations
At week 16 or upon early treatment discontinuation, the mean
total lymphocyte counts had decreased from baseline by
052 9 109 cells L1 in both the LAS41008 and Fumaderm®
groups, and by 008 9 109 cells L1 in the placebo group.
Similarly, the mean leucocyte counts had decreased from base-
line by 073 9 109 and 069 9 109 cells L1 in the
LAS41008 and Fumaderm® groups, respectively, compared
with 004 9 109 cells L1 in the placebo group. Lymphocyte
counts below 07 9 109 cells L1 were observed during the
trial in 22 patients in the LAS41008 group (79%), 21 patients
in the Fumaderm group (74%) and one patient in the pla-
cebo group (07%). Based on the available follow-up data,
white blood cell counts progressively recovered after treatment
with either LAS41008 or Fumaderm® was stopped.
Serum creatinine values are described in Appendix S1 (see
Supporting Information).
Discussion
Fumaric acid esters are a well-established treatment option
with a long record of a favourable efficacy and safety profile
for adults with moderate-to-severe chronic plaque psoriasis. In
Germany, a combination of FAEs is the most frequently pre-
scribed systemic treatment for patients with moderate-to-
severe psoriasis. In the Netherlands and Austria, FAEs can be
dispensed by pharmacies. Furthermore, FAEs are being used in
other European countries such as Ireland,18 Italy19 and the
U.K.20,21
Table 3 Adverse events (AEs) reported by ≥ 5% of the patients in any
treatment group (safety population)
LAS41008
(n = 279)
Fumaderm®
(n = 283)
Placebo
(n = 137)
At least one TEAE,
n (%)
234 (839) 238 (841) 82 (599)
Preferred term, n (%)
Diarrhoea 108 (387) 113 (399) 23 (168)
Upper
abdominal pain
56 (201) 64 (226) 11 (80)
Abdominal pain 55 (197) 45 (159) 7 (51)
Nausea 30 (108) 24 (85) 5 (36)
Flatulence 15 (54) 16 (57) 7 (51)
Vomiting 13 (47) 19 (67) 2 (15)
Pruritus 24 (86) 28 (99) 15 (109)
Erythema 27 (97) 23 (81) 3 (22)
Skin burning
sensation
22 (79) 20 (71) 3 (22)
Nasopharyngitis 18 (65) 23 (81) 13 (95)
Flushing 51 (183) 46 (163) 2 (15)
Lymphopenia 28 (100) 30 (106) 0
Eosinophilia 25 (90) 17 (60) 0
Headache 23 (82) 23 (81) 14 (102)
TEAE, treatment-emergent AE.
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This randomized, double-blind, placebo-controlled trial has
shown that LAS41008 (DMF) is effective for the treatment of
psoriasis and can provide an efficacy and safety profile compa-
rable with the equivalent dose of DMF contained in the
approved combination of FAEs (Fumaderm®). While
LAS41008 (DMF) is not significantly different from Fuma-
derm® in clinical terms, it may prove easier to access across
the European Union, depending on the different national
healthcare systems.
International psoriasis guidelines recommend the use of
FAEs for the induction and long-term management of the dis-
ease.16 A recent systematic review analysed the data from six
randomized active or placebo-controlled trials of FAEs of
12–16 weeks’ duration, which included 544 patients with
psoriasis.22 Although the end points differed between studies,
all studies assessing PASI reported a significant reduction in
score from baseline with FAEs compared with placebo. PASI
scores were reduced by 71% (vs. 6% with placebo) at week 12
(P < 0001) in one study and 678% in another (vs. 102% with
placebo) at week 16 (P < 0001). A recent systematic review of
fumarate use in psoriasis provided similar data.23
Retrospective data from a German nationwide patient reg-
istry do not show an increased risk for the development of
infections or malignancies for patients on long-term treatment
with FAEs.24
Another meta-analysis that included 16 double-blind, ran-
domized controlled trials of various psoriasis treatments
indicated that FAEs appear to be as effective as high-dose etaner-
cept.25 Furthermore, in an open study of 101 patients with
severe psoriasis, an improvement in PASI of 80% was reported
after 4 months of treatment with FAEs.26 The efficacy of FAEs
has also been reported in a number of observational studies,9,27
with one reporting similar efficacy to methotrexate28 and
another retrospective study showing that 76% of patients
achieved PASI 75 at 1 year.29 This is similar to responses
reported in a large retrospective trial, where 82% of patients
were documented as markedly improved or clear after
36 months of therapy with FAEs, as assessed with the PGA.9
The BRIDGE trial has shown that LAS41008 (DMF) is non-
inferior to the approved combination of FAEs (Fumaderm®),
suggesting that DMF is the main active moiety of Fumaderm®,
with MEF salts not being essential to achieving a clinically rel-
evant response.
Adverse events were more frequent in the LAS41008 and
Fumaderm® groups compared with placebo; however, most
were considered ‘mild’ in severity, mainly comprising gastroin-
testinal disorders and flushing, which are known side-effects of
FAEs.22 Gastrointestinal tolerance can be improved by gradually
increasing the dose at treatment initiation, administering the
dose with food and temporarily reducing the dose in the case of
intolerance.16 In this trial, the safety profile of LAS41008 (DMF)
was very similar to that of Fumaderm®, and no major or unex-
pected safety concerns were identified.
Lymphopenia is a known potential side-effect of FAEs. In
this trial, lymphopenia was reported in 100% of patients
treated with LAS41008 and in 106% of patients treated with
Fumaderm® after 16 weeks. Data from case series suggest
that FAE-induced lymphopenia is usually mild, can be man-
aged with dose adjustments, and reverts upon treatment dis-
continuation.30 The development of severe lymphopenia can
increase the risk of rare opportunistic infections. As of
November 2015, nine cases of progressive multifocal
leucoencephalopathy (PML) have been linked to the use of
Fumaderm® for psoriasis since 1994. PML is a rare, progres-
sive, life-threatening, brain-demyelinating disease caused by
an opportunistic infection with the JC virus. It has also been
described in Patients being treated with Psorinovo (FAE
combination) for psoriasis and with Tecfidera (DMF) for
multiple sclerosis.
There is a direct relationship between low lymphocyte
numbers and PML.9 To minimize the risk of PML, it is advised
not to start treatment with FAEs in patients with abnormal
baseline lymphocyte counts, and to monitor lymphocyte
counts on a regular basis. It is recommended to reduce the
treatment dosage if lymphocyte counts decrease below
07 9 109 cells L1 and to stop the treatment dose if lympho-
cyte counts do not increase a month after dose reduction, or
if they fall below 05 9 109 cells L1.16,31
There were limitations to this trial. The primary efficacy
end points were measured after only 16 weeks of treatment,
of which up to 9 weeks was needed to titrate to the therapeu-
tic dose. This relatively short treatment period may not allow
provision of an estimate of the maximum efficacy, considering
that the efficacy of FAEs is seen to improve over many months
of treatment and continues up to 36 months of treatment.9
Discontinuation rates were relatively high, due mainly to the
known side-effect profile of FAEs; in this context, the last-
observation-carried-forward approach may have diminished
the reported treatment effect.
In conclusion, this trial has demonstrated the efficacy and
safety of LAS41008 (DMF) for adults with moderate-to-severe
chronic plaque psoriasis, showing it to be significantly supe-
rior to placebo and noninferior to the approved combination
of FAEs (Fumaderm®). The safety profile of LAS41008 was
very similar to that of Fumaderm®, and no unexpected safety
issues were detected. Once approved, LAS41008 (DMF) will
represent a promising new oral treatment option for patients
with moderate-to-severe psoriasis across Europe.
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